drugset
drugset / Trial / NCT03939533

Study to Monitor Subcutaneous Human Immunoglobulin Administered at Modified Dosing Regimens in Patients With Primary Immunodeficiency Diseases

NCT03939533 ↗

Phase 3 Completed 64 enrolled Octapharma
RandomizedParallel-groupOpen-labelTreatment

Summary

CLINICAL PHASE 3 STUDY TO MONITOR THE SAFETY, TOLERABILITY, AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (CUTAQUIG®) ADMINISTERED AT MODIFIED DOSING REGIMENS IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES

Timeline

Start
2019-10-17
Primary completion
2022-01-03
Completion
2022-01-03

Drugs

EvaluationDrugModalityDoseRoute
Subject CUTAQUIG Protein / enzyme biologic — Subcutaneous

Indications

inborn error of immunity